Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma

@article{Mohamed2011PatientBP,
  title={Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma},
  author={Ms Ateesha F. Mohamed and A. Brett Hauber and Maureen P. Neary},
  journal={PharmacoEconomics},
  year={2011},
  volume={29},
  pages={977-988}
}
Background: Angiogenesis inhibitor agents have been shown to be effective in increasing progression-free survival (PFS) in patients with renal cell carcinoma (RCC); however, these treatments have different toxicity profiles. Objective: Our objective was to quantify patients’ benefit-risk preferences for RCC treatments and relative importance of attributes in a common metric. Methods: US residents aged ≥18 years with RCC completed a web-enabled, choice-format conjoint survey that presented a… CONTINUE READING
Highly Cited
This paper has 33 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 16 citations